



(51) International Patent Classification:

C07K 16/24 (2006.01) *A61P 11/06* (2006.01)
A61K 9/00 (2006.01) *A61P 37/08* (2006.01)

(21) International Application Number:

PCT/IB2016/055336

(22) International Filing Date:

7 September 2016 (07.09.2016)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/215,904 9 September 2015 (09.09.2015) US
62/216,050 9 September 2015 (09.09.2015) US
62/342,511 27 May 2016 (27.05.2016) US

(71) Applicant (for all designated States except US): NO-VARTIS AG [CH/CH]; Lichtstrasse 35, 4056 Basel (CH).

(72) Inventors; and

(71) Applicants (for US only): RONDEAU, Jean-Michel
Rene [FR/FR]; Novartis Pharma AG, Postfach, 4002 Basel

(CH). EDWARDS, Matthew John [GB/GB]; 19 Millais, Horsham Sussex RH13 6BS (GB). MILLER, Danforth [US/US]; Novartis Pharmaceuticals Corporation, 150 Industrial Road, San Carlos, California 94070 (US). HUANG, Daniel [US/US]; Novartis Pharmaceuticals Corporation, 150 Industrial Road, San Carlos, California 94070 (US). HEMMIG, Rene [CH/CH]; Novartis Pharma AG, Postfach, 4002 Basel (CH). KNOPF, Hans-Peter [DE/DE]; Novartis Pharma AG, Postfach, 4002 Basel (CH). GUPTA, Kapil [US/US]; 92 Border Road, Concord, Massachusetts 01742 (US). VAN HEEKE, Gino Anselmus [GB/GB]; 1, Tudor Drive, Upper Beeding BN44 3HP (GB). HAUBST, Nicole [DE/DE]; Morphosys AG, Lena-Christ-Strasse 48, 82152 Planegg (DE). ANDLAUER, Barbara [DE/DE]; Morphosys AG, Lena-Christ-Strasse 48, 82152 Planegg (DE).

(74) Common Representative: NOVARTIS AG; Lichtstrasse 35, 4056 Basel (CH).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,

[Continued on next page]

(54) Title: THYMIC STROMAL LYMPHOPOIETIN (TSLP)-BINDING ANTIBODIES AND METHODS OF USING THE ANTIBODIES

(57) Abstract: The invention provides molecules, e.g., antibodies or antibody fragments, that specifically bind thymic stromal lymphopoietin (TSLP), compositions comprising these molecules, and methods of using and producing these molecules.

Fig. 7





BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,

DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*